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Summary.-In vivo treatment with antineoplastic compounds has been reported to
lead to the expression of new antigenic specificities which were not detected on
parental cells, and which were transmissible as a genetic character. The current
study is concerned with antibody-dependent cellular cytotoxic (ADCC) activity in
serum of syngeneic mice challenged with LY/DTIC cells, a subline of LY murine lym-
phoma, antigenically altered by the drug DTIC. LY/DTIC target cells coated with
LY/DTIC- immune serum were specifically lysed by virgin lymphocytes. The genetic
background of the effector cells, whether syngeneic, allogeneic or xenogeneic, did not
produce significant differences in the percentage of target-cell lysis. ADCC activity
was reduced when the immune serum was added directly to the incubation medium,
without precoating. Although sera from individual animals exhibited different
levels of ADCC activity, they nevertheless followed the general trend of the pooled
sera. Peak activity of ADCC was obtained in the sera collected on Days 8 and 30 after
LY/DTIC cell challenge. The ADCC activity elicited by LY/DTIC cells may contribute
to the rejection of drug-altered tumour cells.
lI VIVC) TREATMENT with antineo-
plastic drugs has been found to increase
the antigenicity of mouse tumour cells
(Melan et al., 1968; Mihich, 1969; Bon-
massar et al., 1970; Nicolin et al., 1972,
Fuji et al., 1973). These new antigenic
specificities were not detected on parental
cells, and were transmissible, as a genetic
character, after the withdrawal of the
drug (Nicolin et al., 1974). The pharmaco-
logically induced antigenic alteration of
tumour cells may lead to their rejection
on inoculation into syngeneic hosts. An
understanding of the immune reactivity
to drug-induced antigens might lead to
new methodologies for the experimental
immunotherapy of murine neoplasms,
designed to eradicate cancer cells totally
(Oettgen, 1977). In a series of previous
studies, drug-xenogenized tumour cells
were found to elicite cellular rather than
humoral immune responses (Testorelli
et al., 1978; Fioretti et al., 1978). Anti-
bodies specific to drug-induced antigens
have been detected by a number ofassays,
including binding of radioiodinated im-
munoglobulin of hyperimmunized syn-
geneic animals (Kitano et al., 1972), a
modified plaque assay (Fuji & Mihich,
1975) and direct, complement-dependent
cytotoxicity (Nicolin et al., 1976a). In
these studies, the activity, though specific
and reproducible, was generally not exten-
sive. In the present study, the serum of
mice challenged with L5178Y lymphoma
cells antigenically altered by treatment
with the anticancer drug 5(3,3-dimethyl
triazeno) imidazole-4-carboxamide (DTIC)
was used to determine the extent of
antibody-dependent cellular cytotoxicity
(ADCC) against the DTIC-altered tumour
cells.P. FRANCO, F. VERONESE, F. LEVI, A. GOLDIN AND A. NICOLIN
MATERIALS AND METHODS
Animals and tumours.-Three-month-old
inbred DBA/2Cr, BALB/c, C57BL/6J, C3H
male mice, hybrid (BALB/cxDBA/2Cr) F1
male mice, hereafter called CD2F1, obtained
from theCharles RiverBreeding Laboratories,
Calco, Italy, and 12-15 week-old Sprague-
Dawley male rats obtained from Farmitalia-
Carlo Erba, Milan, Italy, were used in the
experiments. L5178Y lymphoma (LY) chem-
ically induced in DBA/2 mice (kindly
supplied by Dr P. Alexander, Sutton,
England) was maintained by weekly i.p.
passages in compatible animals. The LY/
DTIC subline was obtained by daily in vivo
treatment ofthe parental LY lymphoma with
DTIC (100 mg/kg i.p.) for 5 transplant
generations, as previously described (Nicolin
et al., 1976b), and maintained by in vivo
passages in CD2F1 mice that had been
immunosuppressed with cyclophosphamide
(200 mg/kg i.p.) 24 h before tumour inocula-
tion.
Drugs.-DTIC (NSC-45388) was dissolved
in chilled saline after addition of equal parts
(w/w) of citric acid. Cyclophosphamide
(NSC-26271) was dissolved in saline im-
mediately before use. Both drugs were
obtained through the courtesy of Dr V. L.
Narayanan, Developmental Therapeutics
Program, Division of Cancer Treatment,
National Cancer Institute, Bethesda, Mary-
land, U.S.A.
Immune sera.-CD2F1 mice were im-
munized against LY/DTIC tumour cells by
i.p. challenge with 107 viable cells or to LY
tumour cells by i.p. challenge of 2x 107
irradiated cells (Securix Compact machine;
50 Gy 200 kV, 12 mA, 0 5 mm Cu-Al filter
1 Gy/min). Blood was obtained from the
retro-orbital sinus at the time indicated,
and sera were heat-inactivated at 560C
for 45 min before use. Hyperimmune sera
were obtained as above, but using 6 immuni-
zations at 2-week intervals. In this case the
first sensitization was s.c. with a 50:50
mixture (v/v) of cell suspension and com-
plete Freund adjuvant.
ADCC assay.-The 51Cr-release micro-
assay (Goldstein & Blomgren, 1973) was used.
Target cells were LY or LY/DTIC, pre-
labelled with Na2 51CrO4 (Amersham) 200
,uCi/107 cells, and effector cells were spleen
cells from virgin animals or circulating
lymphocytes from healthy donors. 51Cr-
labelled target cells (105) in a volume of 100
,ul, pre-incubated with serial dilutions of
the serum, were seeded in V-bottomed
microplates (Sterilin, Teddington, Middlesex)
with 100 jul of different ratios of effector cells
and incubated 4 h at 37°C in a moist atmo-
sphere of950/0 air and 5%/ C02. Alternatively,
target cells and effector cells, in 100 ,ul
final volume, were incubated 4 h in the
presence of 100 IlI of serum. The plates were
centrifuged and 100 ,ul supernatant was
counted in an automatic gamma counter.
The ADCC activity was expressed as
percentage of cytotoxicity as follows:
Specific cytotoxicity=
ct/min in experimental samples -
ct/min in controls*
ct/min in detergent samples -
ct/min in controls
x 100
RESULTS
Serum of animals challenged with a
single inoculum of 10 x 106 viable LY/
DTIC cells did not exhibit complement-
dependent cytotoxicity, but lytic anti-
bodies were obtained after extensive
sensitization with LY/DTIC tumour cells.
In that case, however, specific 51Cr
release did not exceed that of the controls
by more than 20%, and diminished
rapidly on dilution (Fig. 1). Parental LY
target cells were not lysed by anti-LY/
DTIC serum and guinea-pig complement,
nor were either cell types lysed by sera
obtained in syngeneic animals by several
injections of X-inactivated LY cells.
LY/DTIC target cells, coated with
serum from animals challenged with
10 x 106 viable LY/DTIC cells, were lysed
by virgin, syngeneic lymphocytes (Fig. 2).
High and biphasic ADCC activity was
obtained. A peak of target-cell lysis
(about 50%) was detected at a serum
dilution of 1/64, and a second peak was
seen at a dilution of 1/512. A "prozone"
effect, reduced ADCC activity at the
*Controls were labelled target cells incubatedwith normal mouse serum and spleen cells from virginanimals.
Detergent for the maximum-release determination was a 5% water solution ofBrij 35 (BDH, Milan, Italy).
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FIG. 1.-Complement-dependent lyticactivity
of anti-LY/DTIC serum. 5lCr-labelled
LY/DTIC cells (0), or 5lCr-labelled LY
cells (*), were incubated with immune
serum to LY/DTIC cells ( - -), hyper-
immune serum to LYDTIC ( ) and
normal serum (-. .) in the presence of
complement. X-ray-inactivated parental
LY cells injected in CD2F1 mice did not
elicit serum effective in the complement-
dependent lysis, 1:5 rabbit serum pre-
adsorbed on mouse liver cells was the source
of complement.
highest serum concentrations, as reported
by other authors in different tumour
systems, and a fall of activity at serum
dilutions between 1/64 and 1/512 were
seen. Lysis did not occur with LY target
cells or unrelated target cells, nor were
X-ray-inactivated LY cells able to elicit
immune sera with ADCC activity (data
reported here).
Fig. 3 show that cell lysis was obtained
when the ADCC assay was conducted in
the presence of serum during the 4h
inoculation. Although the pattern of
lytic activity was similar to that obtained
with precoating target cells before the
incubation with effector cells (Fig. 2) the
specific percentage of 51Cr release was
significantly reduced.
The genetic background of the effector
cells did not substantially alter the results
of the ADCC assay. As shown in Fig. 4,
the pattern of the reaction was main-
tained, though the peak target-cell lysis
was obtained at a lower dilution (1/32).
The specificity was mediated by anti-LY/
DTIC antibodies, while unprimed cells
from different species have been the Fc+
populations, antibody-dependent for cell
lysis. Anti-LY serum did not show ADCC
activity in the assay with allogeneic or
xenogeneic lymphocytes (data not re-
ported here). The kinetics of antibody
production after challenge with LY/
DTIC cells is reported in Fig. 5. With
syngeneic or allogeneic effector cells, two
peaks of activity were observed: a narrow
peak on Day 8 after the immunizing
inoculum, and a second, broad peak
around the 30th day. Maximum activity
was obtained on Day 8 with syngeneic
effectors, and on Day 30 with allogeneic
lymphocytes. Comparison of the differ-
ences in activity is not possible, since
target cells were coated with serum
diluted 1/64 or 1/32, depending on whether
the effector system was syngeneic or allo-
geneic. Fig. 6 shows the ADCC activity of
serum from individual animals. Target
cells coated with serum from CD2F1 mice
challenged with 10 x 106 LY/DTIC cells
i.p. showed differences in susceptibility to
lysis by C57BL/6J lymphocytes. Despite
the individual variability of the sera in
mediating in vitro ADCC, the pattern of
the activity was similar to that observed
with pooled sera.
DISCUSSION
It is well established that target-cell
destruction can be mediated through
different immunological mechanisms
(Cerottini & Brunner, 1977). Specific cel-
lular lysis of tumour cell is mainly per-
formed by the classic T-cell immunity
mechanism (Cerottini & Brunner, 1974)
or the interaction ofantibody with normal
lymphoid cells, the latter being referred
to as antibody-dependent cellular cyto-
toxicity (ADCC). The precise mechanism
of ADCC is not understood, though it is
known that the specificity of this im-
imunological reaction is determined by
antibody bound to membrane-associated
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FIG. 2. Specific ADCC activity of anti-LY/DTIC sertum. Effector cells were splenic lymphiocytes
from CD2F1 mice. Sera, obtaine(d by bleeding 3 CD2F1 mice 8 days afteri.p. challenge wNith 10 x 106
LY/DTIC cells or with 10 x 106 X-ray-inactivated LY cells (40 Gy) were lheat-inactivated
before use. ADCC anti-LY/DTIC serum was checked against LY/DTIC cells (0 *), LY cells
(0---0), L1210 cells (A ---A) and EL4 cells ( -i-). ADCC anti-LY serum was checked
against LY/DTIC cells (0 - 0e) and LY cells (C 0). The prebleed,s testel against target
cells wsere never above the background(l.
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FIG. 3. Reduced ADCC activity on adding the antiserum to effector and target cells during thle
4h pre-incubation. Effector cells were spleen cells from CD2F1 mice. Serum was obtained as
indicatedt in Fig. 2. 5ICr-labelled targets; were LY/DTIC cells (O) or LY cells (0).
antigens, and that the effector cells bear
receptors for the Fc fragment of the
immunoglobulin molecules (Greenberg et
al., 1975), but the effector cells lack both
T- and B-cell characteristics.
Little is known about the in vivo sig-
nificance of ADCC, which was identified
by means of in vitro experiments, both in
human and animal systems. ADCC has
been demonstrated against cells infected
with a variety of viruses (Lamon et al.,
1976; Shore et al., 1976a) and also against
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FIG. 4. Lysis of antibody-coated LY/DTIC cells I)y xenogenieic oI allogeneic effector cells. Effectoi
cells were spleen cells from 3 outbred Sprague-Dawley rats (O), C57BL/6J mice (S), C3H (El)
or BALB/c mice (A). Serum was obtained from CD2F1 mice 30 (lays after their sensitization wvith
1Ox 106 LY/DTIC cells. Target cells were 51Cr-labellecl LY/DTIC cells.
FIG.
A
I.
fr
SE
I
tumour-associated antigens (Wiinderlich
et al., 1975; Durantez & Zighelboim, 1976),
histocompatibility (Yust et al., 1974;
A@ ~~~ss ,Jeannet & Vassalli, 1976) or auto-antigens
(Feldmann et al., 1976). It would appear
that any cell in which a virus is replicating
has alterecl membrane properties which
make that cell susceptible to destruction
by this mechanism (Shore et al., 1976b).
This would also hold true for tumour
,/ \ ' cells or cells expressing new or altered
\ membrane antigens, if they are strong
eniough to evoke an immune response.
Even though the role of ADCC in vivo
10 3. .and its potential participation in immuno- s 10i 2'0 3'0 410 510 surveillance has still to be defined, the
DAYS AFTER SENSITIZATION high sensitivity of this in vitro assay for
5. Kinetics of serum activity in the detecting low amounts of antibody can .DCC assay after sensitization with have several applications (Trinchieri et al., O x 106 viable LY/DTIC cells. Effector 1973; Zighelboim et al. ] 974a b). els were splenic lymphlocytes from :3 e a Tngeneic CD2F1 mice (0 -O) oi In the present study, a high level of
om3allogeneicC57BL/6Jmice( 0). ADCC activity was shown by serum from erum dilutions w,,,ere 1:64 for CD2F, oiT animals immunized with LY/DTIC cells. :32 for C57BL/6J, respectively. Target Serm from animals sensitized only once
FilS Were 5ICr-labelled 1LY/DTTC cells. e mfrmai lsentzdolvnc
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FiG 6. ADCC activity exhibited by serum from individual CD2F1 mice. Effector cells were
splenic lymphocytes from 3 C57BL/6J. O, e and E represent the specific 51Cr release mediated
by sera from 3 individual CD2F1 mice sensitized 8 (lays before bleeding wN-ith 10 x 106 LY/DTIC
cells. Target cells were 5ICr-labelled LY/DTIC cells.
with LY/DTIC cells mediated high ADCC
activity ( 50% cell lysis) in contrast with
no activity in the direct, complement-
dependent assay.
Complement,-dependent humoral cyto-
toxicity could be detected (never above
20% specific 51Cr release) in the serum of
animals only after multiple immuniza-
tions, and the activity was lost at serum
dilutions effective in mediating ADCC.
The activity mediated by the sera raised
in syngeneic animals immunized with
LY/DTIC cells was similar to that media-
ted by sera from animals bearing highly
immunogenic tumours or challenged with
histoincompatible cells (Blair et al., 1976).
The current observations with DTIC-
induced antigens are consistent with pre-
vious studies with other transplantation
antigens (de Landazuri et al., 1974:
Berger & Amos, 1977) in that the cyto-
toxic antibody synthesis was very low, in
contrast with the marked synthesis of
binding antibodies effective in the ADCC
assay.
Although the molecular nature of these
antigens has not yet been studied, our
data may contribute to an understanding
of their biological characteristics and to a
definition of their immunological proper-
ties.
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